Axsome’s Auvelity cleared FDA approval for Alzheimer’s agitation, joining the company’s existing Alzheimer franchise and extending access for patients with agitation symptoms. In parallel, Esperion is reported to go private in a $1.1 billion deal, reinforcing consolidation dynamics in cardiometabolic-focused drug development. Together, these headlines illustrate two of the biggest forces shaping biotech near term: regulatory expansion that unlocks new revenue channels, and corporate restructuring that can change ownership and capital allocation. For biotech professionals tracking competitive landscapes, label expansions like Auvelity’s can shift payer conversations and neurologist prescribing patterns, while take-private moves can accelerate strategic repositioning of late-stage assets. The combined package suggests heightened activity in both clinical and financial levers that drive sector outcomes.